普瑞巴林联合硫酸软骨素治疗膝骨性关节炎疼痛患者的效果分析

Effect Analysis of Pregabalin Combined with Chondroitin Sulfate in the Treatment of Patients with Knee Osteoarthritis Pain

目的:探讨普瑞巴林联合硫酸软骨素治疗膝骨性关节炎疼痛患者的效果。方法:选择2019年1月-2020年2月本院收治的膝骨性关节炎患者76例。按照随机数字表法分为对照组和研究组,每组38例。对照组予以硫酸软骨素治疗,研究组予以普瑞巴林联合硫酸软骨素治疗。比较两组膝关节疼痛程度、关节炎严重程度、血清炎性因子水平以及不良反应发生情况。结果:治疗前,两组VAS评分比较,差异无统计学意义(P>0.05)。治疗1、4、8周后,两组VAS评分均降低。治疗1、4、8周后,研究组VAS评分均低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组WOMAC评分比较,差异无统计学意义(P>0.05)。治疗1、4、8周后,两组WOMAC评分均降低。治疗1、4、8周后,研究组WOMAC评分均低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组患者的白细胞介素1(IL-1)、白细胞介素6(IL-6)、白细胞介素8(IL-8)、基质金属蛋白酶3(MMP-3)、基质金属蛋白酶抑制剂1(TIMP-1)水平比较,差异均无统计学意义(P>0.05)。治疗后,两组IL-1、IL-6、IL-8、MMP-3水平均低于治疗前,且研究组均低于对照组(P<0.05)。治疗后,两组TIMP-1水平均高于治疗前,且研究组高于对照组(P<0.05)。研究组不良反应发生率为5.26%,与对照组的2.63%比较,差异无统计学意义(P>0.05)。结论:普瑞巴林联合硫酸软骨素治疗膝骨性关节炎疼痛患者可有效缓解患者疼痛感,降低疾病严重程度,改善血清炎症因子水平,且不良反应发生率较低。

Objective:To explore the effect of Pregabalin combined with Chondroitin Sulfate in the treatment of pain patients with knee osteoarthritis.Method:A total of 76 patients with knee osteoarthritis admitted to our hospital from January 2019 to February 2020 were selected.According to random number table method,they were divided into control group and study group,38 cases in each group.The control group was treated with Chondroitin Sulfate,and the study group was treated with Pregabalin combined with Chondroitin Sulfate.The degree of knee pain,the severity of arthritis,the level of serum inflammatory factors and the incidence of adverse reactions were compared between the two groups.Result:Before treatment,there was no significant difference in VAS scores between the two groups(P>0.05).After 1,4 and 8 weeks of treatment,VAS scores were decreased in both groups.After 1,4 and 8 weeks of treatment,VAS scores in the study group were all lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in WOMAC score between the two groups(P>0.05).After 1,4,and 8 weeks of treatment,WOMAC scores were decreased in both groups.After 1,4 and 8 weeks of treatment,WOMAC scores of the study group were lower than those of the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of interleukin 1(IL-1),interleukin 6(IL-6),interleukin 8(IL-8),matrix metalloproteinase-3(MMP-3)and tissue inhibitor of metalloproteinase-1(TIMP-1)between two groups(P>0.05).After treatment,the levels of IL-1,IL-6,IL-8 and MMP-3 in both groups were lower than those of before treatment,and those in the study group were lower than those in the control group(P<0.05).After treatment,TIMP-1 level in both groups were higher than those of before treatment,and that in the study group was higher than that in the control group(P<0.05).The incidence of adverse reactions in the study group was 5.26%,compared with 2.63%in the control group,the difference was not statistically significant(P>0.05).Conclusion:Pregabalin combined with Chondroitin Sulfate in the treatment of pain in patients with knee osteoarthritis can effectively relieve pain,reduce the severity of the disease,improve the level of serum inflammatory factors,and the incidence of adverse reactions is low.